TWI701041B - 在c5相關疾病之治療或預防中使用的醫藥組成物與治療或預防c5相關疾病的方法 - Google Patents

在c5相關疾病之治療或預防中使用的醫藥組成物與治療或預防c5相關疾病的方法 Download PDF

Info

Publication number
TWI701041B
TWI701041B TW108127358A TW108127358A TWI701041B TW I701041 B TWI701041 B TW I701041B TW 108127358 A TW108127358 A TW 108127358A TW 108127358 A TW108127358 A TW 108127358A TW I701041 B TWI701041 B TW I701041B
Authority
TW
Taiwan
Prior art keywords
days
antibody
hvr
dose
pharmaceutical composition
Prior art date
Application number
TW108127358A
Other languages
English (en)
Chinese (zh)
Other versions
TW202019467A (zh
Inventor
四宮賢治
五反田圭介
西村純一
艾瑞卡 溫特
家瑜 許
Original Assignee
日商中外製藥股份有限公司
瑞士商Ｆ 霍夫曼 拉羅公司
國立大學法人大阪大學
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 日商中外製藥股份有限公司, 瑞士商Ｆ 霍夫曼 拉羅公司, 國立大學法人大阪大學 filed Critical 日商中外製藥股份有限公司
Publication of TW202019467A publication Critical patent/TW202019467A/zh
Application granted granted Critical
Publication of TWI701041B publication Critical patent/TWI701041B/zh

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0021—Intradermal administration, e.g. through microneedle arrays, needleless injectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Transplantation (AREA)
  • Genetics & Genomics (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
TW108127358A 2018-08-01 2019-08-01 在c5相關疾病之治療或預防中使用的醫藥組成物與治療或預防c5相關疾病的方法 TWI701041B (zh)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US201862713211P 2018-08-01 2018-08-01
US62/713,211 2018-08-01
US201862764952P 2018-08-17 2018-08-17
US62/764,952 2018-08-17
US201862760204P 2018-11-13 2018-11-13
US62/760,204 2018-11-13

Publications (2)

Publication Number Publication Date
TW202019467A TW202019467A (zh) 2020-06-01
TWI701041B true TWI701041B (zh) 2020-08-11

Family

ID=67660420

Family Applications (2)

Application Number Title Priority Date Filing Date
TW108127358A TWI701041B (zh) 2018-08-01 2019-08-01 在c5相關疾病之治療或預防中使用的醫藥組成物與治療或預防c5相關疾病的方法
TW109108378A TWI704157B (zh) 2018-08-01 2019-08-01 在c5相關疾病之治療或預防中使用的醫藥組成物與治療或預防c5相關疾病的方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
TW109108378A TWI704157B (zh) 2018-08-01 2019-08-01 在c5相關疾病之治療或預防中使用的醫藥組成物與治療或預防c5相關疾病的方法

Country Status (23)

Country Link
US (1) US20210301004A1 (cg-RX-API-DMAC7.html)
EP (2) EP3829628B1 (cg-RX-API-DMAC7.html)
JP (4) JP6672516B2 (cg-RX-API-DMAC7.html)
KR (5) KR20210038697A (cg-RX-API-DMAC7.html)
CN (1) CN112512563A (cg-RX-API-DMAC7.html)
AU (2) AU2019315213B2 (cg-RX-API-DMAC7.html)
BR (1) BR112021001655A2 (cg-RX-API-DMAC7.html)
CA (1) CA3107618A1 (cg-RX-API-DMAC7.html)
CR (1) CR20210103A (cg-RX-API-DMAC7.html)
DE (1) DE112019003835T5 (cg-RX-API-DMAC7.html)
ES (1) ES2980137T3 (cg-RX-API-DMAC7.html)
HR (1) HRP20240823T1 (cg-RX-API-DMAC7.html)
HU (1) HUE067057T2 (cg-RX-API-DMAC7.html)
IL (1) IL280475B1 (cg-RX-API-DMAC7.html)
MX (2) MX2021000516A (cg-RX-API-DMAC7.html)
MY (1) MY210523A (cg-RX-API-DMAC7.html)
PH (1) PH12021550226A1 (cg-RX-API-DMAC7.html)
PL (1) PL3829628T3 (cg-RX-API-DMAC7.html)
RS (1) RS65630B1 (cg-RX-API-DMAC7.html)
SG (1) SG10202002898RA (cg-RX-API-DMAC7.html)
SM (1) SMT202400271T1 (cg-RX-API-DMAC7.html)
TW (2) TWI701041B (cg-RX-API-DMAC7.html)
WO (1) WO2020027279A1 (cg-RX-API-DMAC7.html)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101463631B1 (ko) 2006-03-31 2014-11-19 추가이 세이야쿠 가부시키가이샤 항체의 혈중 동태를 제어하는 방법
RU2510400C9 (ru) 2007-09-26 2014-07-20 Чугаи Сейяку Кабусики Кайся Способ модификации изоэлектрической точки антитела с помощью аминокислотных замен в cdr
US20110111406A1 (en) 2008-04-11 2011-05-12 Chugai Seiyaku Kabushiki Kaisha Antigen-binding molecule capable of binding to two or more antigen molecules repeatedly
WO2012073992A1 (ja) 2010-11-30 2012-06-07 中外製薬株式会社 複数分子の抗原に繰り返し結合する抗原結合分子
AR103161A1 (es) 2014-12-19 2017-04-19 Chugai Pharmaceutical Co Ltd Anticuerpos antimiostatina y regiones fc variantes así como métodos de uso
AR103162A1 (es) 2014-12-19 2017-04-19 Chugai Pharmaceutical Co Ltd Anticuerpos anti-c5 y métodos para su uso
EP3394098A4 (en) 2015-12-25 2019-11-13 Chugai Seiyaku Kabushiki Kaisha ANTI-MYOSTATIN ANTIBODIES AND METHODS OF USE
EP3494991A4 (en) 2016-08-05 2020-07-29 Chugai Seiyaku Kabushiki Kaisha COMPOSITION FOR THE PROPHYLAXIS OR TREATMENT OF IL-8 RELATED DISEASES

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW201642902A (zh) * 2015-02-27 2016-12-16 Chugai Pharmaceutical Co Ltd 用於治療ｉｌ－６相關疾病的組成物

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
DE3883899T3 (de) 1987-03-18 1999-04-22 Sb2, Inc., Danville, Calif. Geänderte antikörper.
DK0590058T3 (da) 1991-06-14 2004-03-29 Genentech Inc Humaniseret heregulin-antistof
CA2163345A1 (en) 1993-06-16 1994-12-22 Susan Adrienne Morgan Antibodies
US6074642A (en) 1994-05-02 2000-06-13 Alexion Pharmaceuticals, Inc. Use of antibodies specific to human complement component C5 for the treatment of glomerulonephritis
IL138608A0 (en) 1998-04-02 2001-10-31 Genentech Inc Antibody variants and fragments thereof
US6194551B1 (en) 1998-04-02 2001-02-27 Genentech, Inc. Polypeptide variants
US6737056B1 (en) 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
PL220113B1 (pl) 1999-01-15 2015-08-31 Genentech Inc Wariant macierzystego polipeptydu zawierającego region Fc, polipeptyd zawierający wariant regionu Fc o zmienionym powinowactwie wiązania receptora Fc gamma (FcγR), polipeptyd zawierający wariant regionu Fc o zmienionym powinowactwie wiązania noworodkowego receptora Fc (FcRn), kompozycja, wyizolowany kwas nukleinowy, wektor, komórka gospodarza, sposób otrzymywania wariantu polipeptydu, zastosowanie wariantu polipeptydu i sposób otrzymywania wariantu regionu Fc
PT1325033E (pt) 2000-10-10 2010-04-15 Genentech Inc Inibição da activação do complemento c5 para o tratamento e a prevenção da rejeição diferida de um xenoenxertos ou de uma rejeição vascular aguda
ATE360441T1 (de) 2001-08-17 2007-05-15 Tanox Inc Komplement-inhibitoren die an c5 und c5a binden ohne die bildung von c5b zu hemmen
ITMI20021527A1 (it) 2002-07-11 2004-01-12 Consiglio Nazionale Ricerche Anticorpi anti componente c5 del complemento e loro uso
US7361740B2 (en) 2002-10-15 2008-04-22 Pdl Biopharma, Inc. Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis
EP1944320A1 (en) 2002-12-16 2008-07-16 Genentech, Inc. Immunoglobulin variants and uses thereof
US20050169921A1 (en) 2004-02-03 2005-08-04 Leonard Bell Method of treating hemolytic disease
US20070116710A1 (en) 2004-02-03 2007-05-24 Leonard Bell Methods of treating hemolytic anemia
EP2374817B1 (en) 2004-04-13 2017-09-06 F. Hoffmann-La Roche AG Anti-P-selectin antibodies
TWI380996B (zh) 2004-09-17 2013-01-01 Hoffmann La Roche 抗ｏｘ４０ｌ抗體
AU2007225044C1 (en) 2006-03-15 2018-03-29 Alexion Pharmaceuticals, Inc. Treatment of paroxysmal nocturnal hemoglobinuria patients by an inhibitor of complement
US20110111406A1 (en) 2008-04-11 2011-05-12 Chugai Seiyaku Kabushiki Kaisha Antigen-binding molecule capable of binding to two or more antigen molecules repeatedly
PL2328616T3 (pl) 2008-08-05 2015-10-30 Novartis Ag Kompozycje i sposoby dla przeciwciał celujących białko dopełniacza C5
BRPI0921237A2 (pt) 2008-11-10 2015-09-22 Alexion Pharma Inc métodos e composições para o tratamento de distúrbios associados ao complemento
SG183867A1 (en) 2010-03-11 2012-10-30 Rinat Neuroscience Corp ANTIBODIES WITH pH DEPENDENT ANTIGEN BINDING
TWI667346B (zh) 2010-03-30 2019-08-01 中外製藥股份有限公司 促進抗原消失之具有經修飾的FcRn親和力之抗體
KR101638931B1 (ko) * 2013-01-31 2016-07-12 서울대학교산학협력단 보체 관련 질환의 예방 및 치료를 위한 ｃ5 항체 및 방법
AR103162A1 (es) * 2014-12-19 2017-04-19 Chugai Pharmaceutical Co Ltd Anticuerpos anti-c5 y métodos para su uso
EP3402816A1 (en) * 2016-01-11 2018-11-21 Alexion Pharmaceuticals, Inc. Dosage and administration of anti-c5 antibodies for treatment
MA53248A (fr) 2016-01-25 2022-02-16 Takeda Pharmaceuticals Co Anticorps anti-c5 à commutation ph améliorée
EP3700928A1 (en) * 2017-10-26 2020-09-02 Alexion Pharmaceuticals, Inc. Dosage and administration of anti-c5 antibodies for treatment of paroxysmal nocturnal hemoglobinuria (pnh) and atypical hemolytic uremic syndrome (ahus)
MX2020005547A (es) * 2017-12-04 2020-08-20 Ra Pharmaceuticals Inc Moduladores de la actividad del complemento.

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW201642902A (zh) * 2015-02-27 2016-12-16 Chugai Pharmaceutical Co Ltd 用於治療ｉｌ－６相關疾病的組成物

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Fukuzawa T et al., "Long lasting neutralization of C5 by SKY59, a novel recycling antibody, is a potential therapy for complement-mediated diseases.", Scientific Reports, 2017, 7:1080, p. 1-12. *

Also Published As

Publication number Publication date
MY210523A (en) 2025-09-29
PL3829628T3 (pl) 2024-08-19
JP6672516B2 (ja) 2020-03-25
TW202024128A (zh) 2020-07-01
BR112021001655A2 (pt) 2021-05-04
TW202019467A (zh) 2020-06-01
PH12021550226A1 (en) 2021-10-11
KR20210038697A (ko) 2021-04-07
IL280475B1 (en) 2025-12-01
EP3829628B1 (en) 2024-05-15
RS65630B1 (sr) 2024-07-31
KR20200033225A (ko) 2020-03-27
ES2980137T3 (es) 2024-09-30
CR20210103A (es) 2021-03-22
AU2024205486A1 (en) 2024-08-22
SMT202400271T1 (it) 2024-07-09
HRP20240823T1 (hr) 2024-09-27
EP3829628A1 (en) 2021-06-09
IL280475A (en) 2021-03-01
JP2020019769A (ja) 2020-02-06
JP2020079331A (ja) 2020-05-28
EP4445913A3 (en) 2025-01-01
WO2020027279A1 (en) 2020-02-06
KR20210037743A (ko) 2021-04-06
MX2021000516A (es) 2021-04-12
JP2020073608A (ja) 2020-05-14
KR20200033348A (ko) 2020-03-27
KR20240115904A (ko) 2024-07-26
CN112512563A (zh) 2021-03-16
TWI704157B (zh) 2020-09-11
HUE067057T2 (hu) 2024-09-28
MX2025010400A (es) 2025-10-01
CA3107618A1 (en) 2020-02-06
EP3829628C0 (en) 2024-05-15
SG10202002898RA (en) 2020-05-28
US20210301004A1 (en) 2021-09-30
EP4445913A2 (en) 2024-10-16
AU2019315213A1 (en) 2021-03-25
JP2025065367A (ja) 2025-04-17
JP6672533B1 (ja) 2020-03-25
DE112019003835T5 (de) 2021-05-27
AU2019315213B2 (en) 2024-05-02

Similar Documents

Publication Publication Date Title
JP7581292B2 (ja) Ｃ５関連疾患の治療または予防用の医薬組成物およびｃ５関連疾患を治療または予防するための方法
TWI701041B (zh) 在c5相關疾病之治療或預防中使用的醫藥組成物與治療或預防c5相關疾病的方法
RU2832946C2 (ru) Фармацевтическая композиция, предназначенная для применения для лечения или предупреждения связанного с c5 заболевания, и способ лечения или предупреждения связанного с c5 заболевания
RU2786053C2 (ru) Фармацевтическая композиция для применения для лечения или предупреждения с5-связанного заболевания и способ лечения или предупреждения с5-связанного заболевания
HK40040906A (en) A pharmaceutical composition for use in the treatment or prevention of a c5-related disease and a method for treating or preventing a c5-related disease